CSIMarket Company Name, Ticker, Suppliers, else..
 
Kineta Inc   (KANT)
 
Price: $0.3361 $0.05 15.897%
Day's High: $0.337 Week Perf: 31.8 %
Day's Low: $ 0.30 30 Day Perf: 34.44 %
Volume (M): 300 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.30 52 Wk Low: $0.00



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 13
 Employees 4
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Kineta, Inc. is a biopharmaceutical company established through the merger of Yumanity Therapeutics, Inc. and Kineta Operating, Inc. The company develops product candidates through preclinical studies and clinical trials, aiming for regulatory approval and commercialization. Kineta is currently evaluating strategic alternatives to enhance shareholder value, including a proposed merger with TuHURA Biosciences, Inc.


   Company Address: 7683 SE 27th Street Mercer Island 98040 WA
   Company Phone Number: 378-0400   Stock Exchange / Ticker: KANT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -2.2%    
BMY        0.13% 
REGN        4.57% 
SUPN   -1.89%    
UTHR   -4.77%    
VRTX        1.73% 
• View Complete Report
   



Clinical Study

Kineta’s KVA12123 Shows Promising Results in Ongoing Phase 1/2 VISTA101 Study Presented at SITC 2024

Published Fri, Nov 8 2024 2:00 PM UTC

: Kineta, a biotechnology company focused on developing innovative therapies for cancer and other diseases, recently presented updated clinical results from its ongoing Phase 1/2 VISTA101 study of KVA12123 at the Society for Immunotherapy of Cancer (SITC) 2024. This article outlines the key findings from the presentation, with a focus on the safety, efficacy, and future im...
Clinical Study

Advancing Cancer Therapy Kineta Completes Enrollment in Phase 1 Clinical Study for Advanced Solid Tumors

Published Tue, Oct 8 2024 1:00 PM UTC

In a significant milestone for cancer research and treatment, Kineta Inc. has announced the completion of patient enrollment in the monotherapy arm of its VISTA-101 Phase 1 clinical study, aimed at evaluating its investigational treatment for patients with advanced solid tumors. This study represents an important step in the ongoing search for innovative cancer therapies, pa...
Product Service News

Kineta Expands Strategic Partnership with TuHURA Biosciences for KVA12123 Development

Published Wed, Oct 2 2024 8:05 PM UTC

In a significant development for its ongoing pipeline of innovative therapeutic solutions, Kineta, Inc. has announced the extension of its exclusivity and right of first offer agreement with TuHURA Biosciences concerning the promising KVA12123, a VISTA blocking antibody currently in Phase 1 clinical trials. This announcement reaffirms Kineta s commitment to advancing its res...
Stock Market Announcement

Kineta, Inc. Soars to New Heights: Transitioning to OTC Markets as KANT in Pursuit of Innovation,

Published Thu, Sep 19 2024 10:24 PM UTC

In a significant development for the biotechnology sector, Kineta, Inc. (Nasdaq: KTA) has announced its transition from the Nasdaq to the OTC (Over-The-Counter) Markets. This strategic move comes as the company aims to better align its trading platform with its long-term business objectives and market positioning. As of the writing of this article, the share price for Kineta...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 8.67
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.04
Working Capital Ratio 0.11
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.67 $
Revenues (TTM) 0.04 $
Cash Flow (TTM) -
Cash 0.02 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 125,000
Net Income per Employee (TTM) -2,115,750
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.37

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -404 %
Net Margin (MRQ) -315 %
Net Cash Flow Margin (MRQ) -66 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Kineta Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.